Sepul Bio start eerste dosering in fase 3 HYPERION-studie met Sepofarsen voor LCA10
Clermont-Ferrand, France, Wednesday 1 October 2025 – Sepul Bio, an innovative business unit of Théa, dedicated to the advancement of RNA therapies for inherited retinal diseases, has today announced the dosing of its first participants in the Phase 3 HYPERION clinical trial for sepofarsen, in individuals with CEP290- associated Leber Congenital Amaurosis Type 10 (LCA10). “There are currently no […]